Therapy Areas: Respiratory
AstraZeneca reports on voting rights and capital
2 May 2018 -

AstraZeneca Plc (LON:AZN) (NYSE:AZN), a global, science-led biopharmaceutical company, reported on Tuesday that as on 30 April 2018, its issued share capital with voting rights was 1,266,613,555 ordinary shares of USD0.25.

Also, no shares are held in treasury.

Accordingly, the total number of voting rights in AstraZeneca is 1,266,613,555.

According to the company, this figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in AstraZeneca under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

AstraZeneca focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The company also is selectively active in the areas of autoimmunity, neuroscience and infection.